WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?

Abstract

Depression and AnxietyVolume 33, Issue 8 p. 685-688 Editorial WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN? D. Jeffrey Newport M.D., M.S., M.Div., D. Jeffrey Newport M.D., M.S., M.Div. Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Miami, FloridaSearch for more papers by this authorAlan F. Schatzberg M.D., Alan F. Schatzberg M.D. Stanford University School of Medicine, Stanford, CaliforniaSearch for more papers by this authorCharles B. Nemeroff M.D., Ph.D., Corresponding Author Charles B. Nemeroff M.D., Ph.D. Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida Center on Aging, University of Miami Miller School of Medicine, Miami, FloridaCorrespondence to: Charles B. Nemeroff, University of Miami Miller School of Medicine, Clinical Research Building, 1120 NW 14 Street, Suite 1440, Miami, FL 33136. E-mail: cnemeroff@med.miami.eduSearch for more papers by this author D. Jeffrey Newport M.D., M.S., M.Div., D. Jeffrey Newport M.D., M.S., M.Div. Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida Department of Obstetrics and Gynecology, University of Miami Miller School of Medicine, Miami, FloridaSearch for more papers by this authorAlan F. Schatzberg M.D., Alan F. Schatzberg M.D. Stanford University School of Medicine, Stanford, CaliforniaSearch for more papers by this authorCharles B. Nemeroff M.D., Ph.D., Corresponding Author Charles B. Nemeroff M.D., Ph.D. Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida Center on Aging, University of Miami Miller School of Medicine, Miami, FloridaCorrespondence to: Charles B. Nemeroff, University of Miami Miller School of Medicine, Clinical Research Building, 1120 NW 14 Street, Suite 1440, Miami, FL 33136. E-mail: cnemeroff@med.miami.eduSearch for more papers by this author First published: 26 July 2016 https://doi.org/10.1002/da.22535Citations: 23 Disclosures: : Dr. Newport has received research support from Eli Lilly & Company (Lilly), Glaxo SmithKline (GSK), Janssen, National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institutes of Health (NIH), SAGE, Takeda Pharmaceuticals, and Wyeth. He has served on speakers’ bureaus for Astra-Zeneca (AZ), Lilly, GSK, Pfizer and Wyeth, and advisory boards for GSK. Dr. Schatzberg has served as a consultant for Alkermes, Cervel, Clintara, Forum Pharmaceuticals, McKinsey and Company, Myriad Genetics, Neuronetics, Naurex, One Carbon, Pfizer, Takeda, Sunovion, and X-Hale and as a speaker for Merck and Pfizer; he holds equity in Corcept (co-founder), Gilead, Incyte Genetics, Intersect ENT, Merck, Neurocrine, Seattle Genetics, Titan, and X-Hale; and he is listed as an inventor on pharmacogenetic and mifepristone patents from Stanford University. In the last 3 years, Dr. Nemeroff has received research support from NIH. He has served on scientific advisory boards for the American Foundation for Suicide Prevention (AFSP), Anxiety and Depression Association of America (ADAA), Brain and Behavior Research Foundation, Skyland Trail, and Xhale, on the board of directors for AFSP, ADAA, and Gratitude America, and as a consultant to Bracket, Lilly, Lundbeck, Mitsubishi Tanabe Pharma Development America, Roche, SK Pharma, Sunovion, Taisho, Takeda, and Xhale. He has equity in Xhale and stock holdings with Titan Pharmaceuticals, Seattle Genetics, etc. He has received honoraria, royalties, and expert witness fees from various sources. His income sources or equity of $10,000 or more include American Psychiatric Publishing, Xhale and Bracket. He holds patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1) and Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume33, Issue8FOCUS ON BIOLOGICAL TREATMENTS: KETAMINE AND BEYONDAugust 2016Pages 685-688 RelatedInformation